CD4^＋CD25^＋调节性T细胞在原发性肝癌中的表达及临床意义

Expression of CD4^＋ CD25^＋ Treg cell in hepatocellular carcinoma and its clinical significance

目的探讨CD4^＋CD25^＋调节性T细胞在原发性肝细胞癌肿瘤侵袭性、进展以及预后中的价值。方法应用三色免疫荧光标记法通过流式细胞仪对45例来自不同分期的原发性肝癌患者外周血、肿瘤组织和30例正常人外周血CD4^＋、CD8^＋、CD4／CD8、CD4^＋CD25^＋、CD4^＋CD25^＋CTLA4^＋ -T淋巴细胞亚群的比例进行分析比较，以说明原发性肝癌患者的细胞免疫功能状态。结果①原发性肝癌患者外周血淋巴细胞总数及CD4^＋T细胞比例、CD4／CD8比例低于正常对照组[分别为（1．5±0．4）×10^9，（2．1±0．4）×10^9；（27．6±3．3）％，（32．9±5．8）％；1．02±0．26，1．31±0．42]。②原发性肝癌患者外周血中CD4^＋CD25^＋ -Treg及CD4^＋CD25^＋CTLA4^＋ -T细胞占CD4^＋T细胞的比例明显高于正常对照组[分别为（19．2±3．3）％，（8．4±2．5）％；（8．6±2．2）％，（2．1±0．8）％]。原发性肝癌患者不同分期之间上述比例差异有统计学意义（P〈0．05）。③肿瘤组织中CD4^＋CD25^＋CTLA4^＋ -T细胞比例明显高于肿瘤患者外周血中所占的比例（分别为（87．1±4．4）％，（57．3±3．3）％）。结论调节性T细胞在原发性肝癌患者中的数量分布与肿瘤临床分期有明显关系，CD4^＋CD25^＋调节性T细胞数量的增多可以作为判断侵袭性、进展的一个潜在重要指标。

Objective To investigate the role of regulatory T cells in the invation, advancement and prognosis of hepatocellular carcinoma （ HCC ）. Methods The tumor tissue and the peripheral blood were collceted from forty five patients with every stage HCC ;To contrast, the peripheral blood was collected from thirty healthy people at the same time. The population of CD4 ^＋, CD8^＋ , CD4^＋ CD25 ^＋ , CD4^＋ CD25^＋ CTLA4^＋ T subjects was evaluated by flow cytometry. Results （1）The total number of lymphocyte, the proportion of CD4^＋ T cell and ratio of CD4/CD8 in the group of HCC was significantly less than those of the healthy donors[ （ 1.5±0.4） ×10^9 vs（2.1 ±0.4） × 10^9 ;（27.6±3.3）% vs（32.9 ±5.8）% ; 1. 02 ± 0.26 vs 1.31 ± 0.42 ]. （2）The percentages of CD4^＋ CD25^＋ - Treg and CD4^＋ CD25 ^＋ CTLA4 ^＋ - T cells were significantly higher than those of the healthy donors [ 19.2 ± 3.3 ） % vs （ 8.4 ± 2.5 ） % ; （ 8.6± 2.2 ） % vs （2.1 ± 0. 8 ） % ]. And the percentages were obviously different between every stage of HCC. （3）The percentage of CD^＋ CD25^＋ CTLA4^＋ - T cell in tumor tissue was obviously higher than that in the peripheral blood [ （ 87.1± 4.4 ） % vs （ 57.3± 3.3 ） % ]. Conclusions The quantity of regulatory T lymphocyte cells signifieantly correlated with tumor size, tumor thrombus and clinical stage in hepatocellular carcinoma （HCC） patients. And the increase in the number of CD4^＋ CD25 ^＋ - Treg cell may be potential biological markers for invasion, advancement and prognosis of hepatocellular carcinoma （HCC）.